Limited Conclusions Can be Drawn from Study on Limiting Antithrombotic Therapy Beyond One Year for Stent Patients with Atrial Fibrillation
Cardiovascular Research Foundation (CRF)The first randomized trial of its kind was unable to establish non-inferiority of oral anticoagulation (OAC) alone to combined OAC and a single antiplatelet agent (APT) in patients with atrial fibrillation (AF) and stable coronary artery disease beyond one year after stent implantation.